# Nuclide record nct05636618 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct05636618/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct05636618", "NCT05636618" ;
  schema:name "Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors"@en ;
  schema:description "A phase 1/2 trial of [203Pb]VMT-α-NET in neuroendocrine tumours, pancreatic ductal adenocarcinoma and pheochromocytoma and paraganglioma, run by Perspective Therapeutics, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct05636618/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05636618> ;
  nuclide:status "recruiting" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/pheochromocytoma-paraganglioma/> ;
  nuclide:companies <https://nuclide.cc/companies/perspective-therapeutics/> .